Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...